Hundreds gathered in Jarrow to support a group of North East as they march to Westminster to support and protect the NHS.
A four-year-old boy from Sunderland is to become one of the first people to take part in a new study of a rare genetic illness.
A woman from Teesside has been banned from working in care homes after stealing money from a great-grandfather she was looking after.
The NHS body in York which has controversially voted not to pay for IVF treatment for childless couples, says offering help to the estimated 110 couples a year would have cost it around £2m.
Campaigners have criticised the decision by the Vale of York Clinical Commissioning Group, which says it is facing a funding shortage and has to make "tough choices."
It means York is the only area in the UK where women struggling to conceive are denied fertility treatment on the NHS. Critics say that childless couples in the area are victims of a health service postcode lottery - and they are calling for York to fall in line with national guidelines which state that 3 cycles of IVF should be offered to people who match the criteria up to the age of 39.
The NHS in York says it has taken the decision with "a heavy heart", but "the commissioning of IVF services carries a great element of financial risk."
– Dr Tim Hughes, Vale of York CCG
“The commissioning of IVF services carries a great element of financial risk for the CCG and with prevalence data highlighting that approximately 110 couples per year will come forward for IVF treatment, the cost pressure could be as much as £2 million per year.
– Dr Tim Hughes, Vale of York CCG
“To put this into perspective, in a year, £2m equates to either two fully staffed and operational hospital wards, 293 major hip replacements, treatment for more than 21,500 average attendances at Accident and Emergency or 43 qualified nurses employed full time for a year."
An IVF campaigner from York says she is devastated by the decision by NHS bosses in the city not to fund the treatment.
Karen Boardman, 34, from Heworth, has fought against what she calls the "postcode lottery" regarding the treatment, and helps run the York Fertility Network group.
In June, the NHS Vale of York Clinical Commissioning Group's governing body agreed a policy of offering one cycle of IVF to people who met their criteria. But last night NHS managers said there was not enough money to fund the service.
Mrs Boardman said: "I don't know how they can snatch it away from us."
– Dr Emma Broughton, Vale of York CCG, speaking in June
“I am delighted that the Governing Body has formally agreed the criteria, which now means that for the first time in five years, IVF is now going to be available to couples in the local area.”
– Dr Tim Hughes, Vale of York CCG, speaking today
“It is with a heavy heart that I announce the CCG’s Governing Body has voted to temporarily defer the commissioning of IVF services in the Vale of York for 2014-15.
The NHS in York has backtracked on a decision earlier this summer to offer childless couples IVF treatment. The city is the only place in the UK not to offer at least one cycle of IVF.
In June, the NHS Vale of York Clinical Commissioning Group's governing body agreed a policy of offering one cycle of IVF to people who met their criteria. It followed years where the treatment had been denied to people in the area because NHS managers said there was not enough money to fund the service.
But today the governing body narrowly voted not to introduce IVF treatment this year. They will look again at the issue at the end of this financial year.
The manufacturer of a breast cancer drug which has been deemed "too expensive" to be offered by the NHS has hit back at the decision.
Dr Jayson Dallas, general manager of Roche Products Limited, declared it "an incredible injustice."
– Dr Jayson Dallas
Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.
Refusing patients access to this drug is an incredible injustice and tantamount to turning the clock back in cancer research and development. We plan to appeal this decision.
The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
– Sir Andrew Dillon
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
The North East Ambulance Service has found that a number of out-of-date controlled drugs have been administered to patients. In total 75 doses had been administered by 26 paramedics.
The specific medicines were Morphine, Oramorph oral suspension and Diazamuls. Patients were not at risk.
The Care Quality Commission and Monitor is aware of the situation.
– North East Care Homes Ltd, which run Stainton Way care home
"As a care provider we will not tolerate this conduct from any of our employees and we will act accordingly as the company did on this occasion with a good outcome."